iCAD (ICAD) 10-K 28 Mar 22 2021 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Mar. 21, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	ICAD INC
Entity Central Index Key	0000749660
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Document Annual Report	true
Document Transition Report	false
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Trading Symbol	ICAD
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Address, State or Province	NH
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		25,172,491
Entity Public Float			$ 400,889,699
Entity Tax Identification Number	02-0377419
Entity File Number	001-09341
Entity Incorporation, State or Country Code	DE
Entity Address, City or Town	Nashua
Entity Address, Address Line One	98 Spit Brook Road, Suite 100
Entity Address, Postal Zip Code	03062
City Area Code	603
Local Phone Number	882-5200
ICFR Auditor Attestation Flag	false
Auditor Name	BDO USA, LLP
Auditor Firm ID	243
Auditor Location	Boston, Massachusetts

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 34,282	$ 27,186
Trade accounts receivable, net of allowance for doubtful accounts of $268 in 2021 and $111 in 2020	8,891	10,027
Inventory Net	4,171	3,144
Prepaid expenses and other current assets	2,962	1,945
Total current assets	50,306	42,302
Property and equipment:
Equipment	7,121	6,765
Leasehold improvements	172	62
Furniture and fixtures	319	319
Marketing assets	376	376
Total property and equipment	7,988	7,522
Less accumulated depreciation and amortization	7,106	6,778
Property and equipment, net	882	744
Operating lease assets	1,059	1,758
Other assets	899	1,527
Intangible assets, net of accumulated amortization of $8,724 in 2021 and $8,494 in 2020	683	889
Goodwill	8,362	8,362
Total other assets	11,003	12,536
Total assets	62,191	55,582
Current liabilities:
Accounts payable	2,779	2,869
Accrued and other expenses	5,642	7,039
Lease payable, current	889	726
Deferred revenue, current	5,652	6,117
Total current liabilities	14,962	16,751
Lease payable, long-term	266	1,075
Deferred revenue, long-term	441	267
Notes payable, long-term	0	6,960
Deferred tax	5	4
Total liabilities	15,674	25,057
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 60,000,000 shares; issued 25,326,086 in 2021 and 23,694,406 in 2020. Outstanding 25,140,255 in 2021 and 23,508,575 in 2020.	253	236
Additional paid-in capital	300,859	273,639
Accumulated deficit	(253,180)	(241,935)
Treasury stock at cost, 185,831 shares in 2021 and 2020	(1,415)	(1,415)
Total stockholders' equity	46,517	30,525
Total liabilities and stockholders' equity	$ 62,191	$ 55,582

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 268	$ 111
Intangible assets, accumulated amortization	$ 8,724	$ 8,494
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	25,326,086	23,694,406
Common stock, shares outstanding	25,140,255	23,508,575
Treasury stock, shares	185,831	185,831

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 33,638	$ 29,698	$ 31,340
Cost of Revenue:
Total cost of revenue	9,395	8,344	7,113
Gross profit	24,243	21,354	24,227
Operating expenses:
Engineering and product development	9,194	8,114	9,271
Marketing and sales	15,135	13,312	13,634
General and administrative	10,406	9,117	7,443
Amortization and depreciation	240	199	276
Total operating expenses	34,975	30,742	30,624
Loss from operations	(10,732)	(9,388)	(6,397)
Interest expense	(141)	(476)	(784)
Interest income	15	97	344
Loss on extinguishment of debt	(386)	(341)	0
Loss on fair value of convertible debentures	0	(7,464)	(6,671)
Other expense, net	(512)	(8,184)	(7,111)
Loss before income tax expense	(11,244)	(17,572)	(13,508)
Income tax expense	1	38	43
Net loss and comprehensive loss	$ (11,245)	$ (17,610)	$ (13,551)
Net loss per share:
Basic	$ (0.45)	$ (0.80)	$ (0.74)
Diluted	$ (0.45)	$ (0.80)	$ (0.74)
Weighted average number of shares used in computing net loss per share:
Basic	24,778	22,140	18,378
Diluted	24,778	22,140	18,378
Product [Member]
Revenue:
Total revenue	$ 21,191	$ 18,903	$ 19,767
Cost of Revenue:
Total cost of revenue	5,653	5,000	3,278
Service [Member]
Revenue:
Total revenue	12,447	10,795	11,573
Cost of Revenue:
Total cost of revenue	3,425	2,965	3,438
Amortization and depreciation [Member]
Cost of Revenue:
Total cost of revenue	$ 317	$ 379	$ 397

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2017			$ 218,914
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations			(198)
Issuance of common stock pursuant to stock option plans			1,396
Stock-based compensation			1,169
Ending Balance at Dec. 31, 2018	$ 6,896	$ 171	230,615	$ (210,774)	$ (1,415)
Ending Balance, shares at Dec. 31, 2018		17,066,510
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations	(196)	$ 2
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations, shares		167,843
Issuance of common stock pursuant to stock option plans	1,400	$ 4
Issuance of common stock pursuant to stock option plans, shares		429,980
Issuance of common stock, net	9,353	$ 19	9,334
Issuance of common stock, net, shares		1,881,818
Stock-based compensation	1,169
Net loss	(13,551)			(13,551)
Ending Balance at Dec. 31, 2019	5,071	$ 196		(224,325)	(1,415)
Ending Balance, shares at Dec. 31, 2019		19,546,151
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations	(225)	$ 0	(225)
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations, shares		97,830
Issuance of common stock pursuant to stock option plans	$ 729	$ 1	728
Issuance of common stock pursuant to stock option plans, shares	155,149	155,149
Issuance of common stock, net	$ 18,284	$ 20	18,264
Issuance of common stock, net, shares		2,033,204
Issuance of common stock pursuant employee stock purchase plan	268	$ 1	267
Issuance of common stock pursuant employee stock purchase plan, shares		42,606
Issuance of common stock upon conversion of debentures	21,164	$ 18	21,146
Issuance of common stock upon conversion of debentures, shares		1,819,466
Stock-based compensation	2,844		2,844
Net loss	(17,610)			(17,610)
Ending Balance at Dec. 31, 2020	30,525	$ 236	273,639	(241,935)	(1,415)
Ending Balance, shares at Dec. 31, 2020		23,694,406
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations	(59)	$ 1	(60)
Issuance of common stock relative to vesting of restricted stock shares forfeited for tax obligations, shares		44,706
Issuance of common stock pursuant to stock option plans	$ 1,027	$ 2	1,025
Issuance of common stock pursuant to stock option plans, shares	168,450	168,450
Issuance of common stock, net	$ 23,229	$ 14	23,215
Issuance of common stock, net, shares		1,393,738
Issuance of common stock pursuant employee stock purchase plan	257	$ 0	257
Issuance of common stock pursuant employee stock purchase plan, shares		24,786
Stock-based compensation	2,783		2,783
Net loss	(11,245)			(11,245)
Ending Balance at Dec. 31, 2021	$ 46,517	$ 253	$ 300,859	$ (253,180)	$ (1,415)
Ending Balance, shares at Dec. 31, 2021		25,326,086

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Common Stock [Member]
Shares forfeited for tax obligations	5,196	20,247	29,887
Additional Paid-in Capital [Member]
Shares forfeited for tax obligations	5,196	20,247	29,887

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flow from operating activities:
Net loss	$ (11,245,000)	$ (17,610,000)	$ (13,551,000)
Adjustments to reconcile net loss to net cash used for operating activities:
Amortization	230,000	309,000	377,000
Depreciation	327,000	268,000	297,000
Bad debt provision	167,000	94,000	62,000
Stock-based compensation expense	2,783,000	2,844,000	1,169,000
Amortization of debt discount and debt costs	17,000	78,000	149,000
Loss on extinguishment of debt	386,000	341,000	0
Deferred tax	1,000	1,000	1,000
Loss on disposal of assets	97,000
Change in fair value of convertible debentures		7,464,000	6,671,000
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	969,000	(302,000)	(3,478,000)
Inventory	(1,027,000)	(533,000)	(1,024,000)
Prepaid and other assets	391,000	(1,390,000)	294,000
Accounts payable	(90,000)	878,000	836,000
Accrued and other expenses	(2,123,000)	(207,000)	982,000
Deferred revenue	(291,000)	780,000	108,000
Total adjustments	1,837,000	10,625,000	6,444,000
Net cash used for operating activities	(9,408,000)	(6,985,000)	(7,107,000)
Cash flow used for investing activities:
Additions to patents, technology and other	(24,000)	(13,000)	(10,000)
Additions to property and equipment	(563,000)	(461,000)	(296,000)
Net cash used for investing activities	(587,000)	(474,000)	(306,000)
Cash flow from financing activities:
Issuance of common stock for cash, net	23,229,000	18,285,000	9,353,000
Issuance of common stock pursuant to Employee Stock Purchase Plan	257,000	266,000
Issuance of common stock pursuant to stock option plans	1,027,000	729,000	1,400,000
Taxes paid related to restricted stock issuance	(59,000)	(225,000)	(196,000)
Principal payments of capital lease obligations			(16,000)
Proceeds from notes payable		6,957,000
Principal repayment of notes payable	(7,363,000)	(4,638,000)	(2,000,000)
Debt issuance costs		(42,000)
Proceeds from line of credit		775,000	3,000,000
Repayment line of credit		(2,775,000)	(1,000,000)
Net cash provided by financing activities	17,091,000	19,332,000	10,541,000
Increase in cash and equivalents	7,096,000	11,873,000	3,128,000
Cash and equivalents, beginning of period	27,186,000	15,313,000	12,185,000
Cash and equivalents, end of period	34,282,000	27,186,000	15,313,000
Supplemental disclosure of cash flow information:
Interest paid	172,000	272,000	643,000
Taxes paid	0	38,000	43,000
Right-of-use assets obtained in exchange for new operating lease liabilities	79,000	69,000	3,105,000
Issuance of common stock upon conversion of debentures	$ 0	$ 21,164,000	$ 0

Organization and Business

Organization and Business	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Note 1 – iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a global medical technology company providing innovative cancer detection and therapy solutions. The Company operates in two The Company maintains its headquarters and a separate manufacturing facility in Nashua, New Hampshire, an operations, research, development, manufacturing and warehousing facility in San Jose, California, and an office in Lyon, France.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies	Note 2 – Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation. Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 return to prior levels. The COVID-19 COVID-19 COVID-19; March 2022 COVID-19 Although the Company did not see any material impact to trade accounts receivable losses in the year ended December 31, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19 Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less and which are unrestricted as to timing or method of withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000 per depositor. Historically, the Company has not experienced any losses related to these balances Financial instruments Financial instruments consist of cash and cash equivalents, trade accounts receivable, contract assets, accounts payable, accrued and other expenses and notes payable. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2021 and 2020. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are initially established through a process of reviewing the financial history and stability of each customer and the Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. Included in accounts receivable at December 31, 2021 are unbilled receivables of approximately $0.4 million which are scheduled t o The Company’s policy is to maintain allowances for potential losses resulting from the inability of a portion of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its allowance for doubtful accounts. An amount is written off against the allowance after all attempts to collect the receivable have failed. Inventory The Company uses the first-in, first-out The Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which is generally three Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of Goodwill, include the following: • significant and sustained underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the Company’s assets in the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant and sustained decline in the Company’s stock price; and • a decline in the Company’s market capitalization below net book value. The two reporting units within iCAD are its segments, Detection and Therapy. The Company records an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of its annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. Fair values for the reporting units are based on a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as the fact that market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to our business profile, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. Equally important, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company assesses each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. The Company performed the annual impairment assessment at October 1, 2021 and compared the fair value of each reporting unit to its carrying value as of this date. The fair value of the Detection reporting unit exceeded the carrying value. Accordingly, impairment of goodwill was recorded. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. Long Lived Assets In accordance with FASB ASC Topic 360 , “Property, Plant an d Equipment” (“ASC 360 ”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360 -10 -35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360 -10 -35 -21 the following factors are examples of events or changes in circumstances that indicate t h • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). In accordance with ASC 360-10-35-17, The Company did record any impairment charges on its long-lived assets for the years ended December , or December , . Intangible assets subject to amortization consist primarily of patents, technology intangibles, trade names, customer relationships and distribution agreements purchased in the Company’s previous acquisitions. These assets are amortized on a straight-line basis or the pattern of economic benefit over their estimated useful lives of 5 to 10 years. Leases Per ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is an operating or financing contract, or part of a contract, that conveys the right to control the use of an identified tangible asset for a period of time in exchange for consideration. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company grants to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows ASC 718, “Compensation – Stock Compensation” re-measured will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, and the number of options that will be forfeited prior to the completion of their vesting requirements. The Company estimates forfeitures based on historical experience with pre-vested Revenue Recognition In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services and the amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. The Company applies the following five steps to guide revenue recognition: 1) Identify the contract(s) with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price , 4) Allocate the transaction price to the performance obligations in the contract that performance obligation or to a distinct good or service that forms part of a performance obligation. The Company determines SSP based on the price at which the performance obligation is sold separately. If the SSP is not observable through past transactions, the Company estimates the SSP taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. 5) Recognize revenue when (or as) the Company satisfies a performance obligation The Company recognizes revenue from its contracts with customers primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when control of the promised goods or services is transferred to a customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. For iCAD’s typical product revenue, control typically transfers upon shipment as title and risk of loss have passed to the customer. Services and supplies are considered to be transferred as the services are performed or over the term of the service or supply agreement. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Perpetual software license are accounted for as a single performance obligation and revenue is recognized at the point in time when ownership is transferred to the customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of revenue. The Company continues to provide for estimated warranty costs on original product warranties at the time of sale. Goods and Services Classifications Products . Product revenue consists of sales of cancer detection perpetual licenses, cancer therapy systems, cancer therapy applicators, cancer therapy disposable applicators and other accessories that are typically shipped with a cancer therapy system. The Company transfers control and recognizes a sale when the product is shipped from the manufacturing or warehousing facility to the customer. Service Contracts 12 48 Supply and Source Usage Agreements . Revenue from supply and source usage agreements is recognized on a straight-line basis over the term of the supply or source agreement. Professional Services . Revenue from fixed fee service contracts is recognized on a straight-line basis over the term of the agreement. Revenue from professional service contracts entered into with customers on a time and materials basis is recognized over the term of the agreement in proportion to the costs incurred in satisfying the obligations under the contract. Other . Other revenue consists primarily of miscellaneous products and services. The Company transfers control and recognizes a sale when the installation services are performed or when the Company ships the product from the Company’s manufacturing or warehouse facility to the customer. Significant Judgments The Company’s contracts with customers may include promises to transfer multiple products and services to a customer and identifying distinct performance obligations that should be accounted for separately versus together may require significant judgment. For arrangements with multiple performance obligations, the Company allocates revenue to each performance obligation based on its relative standalone selling price. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company generally determines standalone selling prices based on the prices charged to customers and uses a range of amounts to estimate standalone selling prices when the Company sells each of the products and services separately and need to determine whether there is a discount that needs to be allocated based on the relative standalone selling prices of the various products and services. The Company typically has more than one range of standalone selling prices for individual products and services due to the stratification of those products and services by customers and circumstances. In these instances, the Company may use information such as the type of customer and geographic region in determining the range of standalone selling prices. The Company may provide credits or incentives to customers, which are accounted for as variable consideration when estimating the transaction price of the contract and amounts of revenue to recognize. The amount of variable consideration to include in the transaction price is estimated at contract inception using either the estimated value method or the most likely amount method based on the nature of the variable consideration. These estimates are updated at the end of each reporting period as additional information becomes available and revenue is recognized only to the extent that it is probable that a significant reversal of any amounts of variable consideration included in the transaction price will not occur. The Company provides for estimated warranty costs on original product warranties at the time of sale. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes incremental costs of obtaining a contract with a customer as an asset if the Company expects the benefit of those costs to be longer than one year and as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. Right to Invoice Where applicable, the Company recognizes revenue from a contract with a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date and the amount to which the Company has a right to invoice. Sales and Other Similar Taxes The Company excludes sales taxes and similar taxes from the measurement of transaction price and ensures compliance w Significant Financing Component The Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. Promised Goods or Services that are Immaterial in the Context of a Contract The Company assesses materiality of promised goods or services as performance obligations in the context of a contract and the Company does not aggregate and assess immaterial items at the entity level. When determining whether a good or service is immaterial in the context of a contract, the assessment will be made based on the application of ASC 606 at the contract level. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed. Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty costs have not historically been material to the Company’s consolidated financial statements. Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials are expensed as incurred. Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2021, 2020 and 2019 was approximately $689,000, $274,000, and $1,101,000, respectively. Income Taxes The Company follows the liability method under ASC Topic 740 “ Income Taxes

Recently Issued Accounting Stan

Recently Issued Accounting Standards	12 Months Ended
	Dec. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recently Issued Accounting Standards	Note 3 – Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, “Financial (“ASU 2016-13”), ASU 2016-13 2016-13 2016-13 2016-13 statements. In December 2019, the FASB issued ASU 2019-12, 2019-12”). 2019-12 ASU 2019-12 is ASU 2019-12 resulted to non-income tax

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4 – Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “ Fair Value Measurement and Disclosures • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying balance sheet are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousand): Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 — — $ 30,573 Total Assets $ 30,573 — — $ 30,573 Fair Value Measurements (in thousands) as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 24,635 $ — $ — $ 24,635 Total Assets $ 24,635 $ — $ — $ 24,635 The following is a roll forward of the Company’s Level 3 instruments for the years ended December 31, 2021 and 2020: Convertible Debentures Balance, December 31, 2019 $ 13,642 Issuances — Fair value adjustments 7,522 Conversion (21,164 ) Balance, December 31, 2020 $ — There were no Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. There were no items measured at fair value on a nonrecurring basis as of or during the years ended December 31, 2021 and 2020.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Note 5 – Revenue Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition and sales channel, reconciled to its reportable segments (in thousands). Year ended December 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 15,661 $ 7,924 $ 23,585 Service contracts 6,358 1,517 7,875 Supply and source usage agreements — 2,089 2,089 Professional services — 89 89 $ 22,019 $ 11,619 $ 33,638 Timing of Revenue Recognition Goods transferred at a point in time $ 15,584 $ 8,012 $ 23,596 Services transferred over time 6,435 3,607 10,042 $ 22,019 $ 11,619 $ 33,638 Sales Channels Direct sales force $ 14,713 $ 4,421 $ 19,134 OEM partners 7,306 — 7,306 Channel partners — 7,198 7,198 $ 22,019 $ 11,619 $ 33,638 Year ended December 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,291 $ 4,535 $ 20,826 Service contracts 5,661 1,333 6,994 Supply and source usage agreements — 1,804 1,804 Professional services — 29 29 Other 45 — 45 $ 21,997 $ 7,701 $ 29,698 Timing of Revenue Recognition Goods transferred at a point in time $ 16,332 $ 4,624 $ 20,956 Services transferred over time 5,665 3,077 8,742 $ 21,997 $ 7,701 $ 29,698 Sales Channels Direct sales force $ 13,809 $ 3,773 $ 17,582 OEM partners 8,188 — 8,188 Channel partners — 3,928 3,928 $ 21,997 $ 7,701 $ 29,698 Year ended December 31, 2019 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,788 $ 4,957 $ 21,745 Service contracts 5,370 1,814 7,184 Supply and source usage agreements — 2,036 2,036 Professional services — 153 153 Other 161 61 222 $ 22,319 $ 9,021 $ 31,340 Timing of Revenue Recognition Goods transferred at a point in time $ 16,949 $ 5,391 $ 22,340 Services transferred over time 5,370 3,630 9,000 $ 22,319 $ 9,021 $ 31,340 Sales Channels Direct sales $ 11,968 $ 5,804 $ 17,772 OEM partners 10,351 — 10,351 Channel partners — 3,217 3,217 $ 22,319 $ 9,021 $ 31,340 Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 8,891 $ 10,027 Current contract assets, which are included in “Prepaid and other assets” $ 1,895 $ 481 Non-current $ 844 $ 1,434 Contract liabilities, which are included in “Deferred revenue” $ 6,093 $ 6,384 The Company records a receivable when revenue is recognized prior to receipt of cash payments and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Contract liabilities, or deferred revenue from contracts with customers, is primarily composed of fees related to long-term service arrangements, which are generally billed in advance. Deferred revenue also includes payments for installation and training that has not yet been completed and other offerings for which the Company has been paid in advance and earn the revenue when it transfers control of the product or service. Changes in deferred revenue from contracts with customers were as follows (in thousands): Year Ended Year Ended Balance at beginning of period $ 6,384 $ 5,604 Deferral of revenue 12,315 11,212 Recognition of deferred revenue (12,606 ) (10,432 ) Balance at end of period $ 6,093 $ 6,384 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $7.1 million in 2022, $1.2 million in 2023, $1.0 million in 2024, and $1.0 million in 2025. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if it expects the benefit of those costs to be longer than one year. Certain commission programs implemented by the Company require costs to be capitalized. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets as of December 31, 2021 and 2020, respectively. Changes in the balance of capitalized costs to obtain a contract were as follows (in thousands): Years Ended December 31, 2021 2020 Balance at beginning of period $ 406 $ 379 Deferral of costs to obtain a contract 249 157 Recognition of costs to obtain a contract (353 ) (130 ) Balance at end of period $ 302 $ 406

Net Loss per Common Share (1o)

Net Loss per Common Share (1o)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Common Share (1o)	Note 6 – Net Loss per Common Share (1o) The Company follows FASB ASC 260-10, A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2021 2020 2019 Net loss available to common shareholders $ (11,245 ) $ (17,610 ) $ (13,551 ) Basic shares used in the calculation of earnings per share 24,778 22,140 18,378 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 24,778 22,140 18,378 Net loss per share Basic $ (0.45 ) $ (0.80 ) $ (0.74 ) Diluted $ (0.45 ) $ (0.80 ) $ (0.74 ) The following table summarizes the number of shares of common stock for convertible securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: Year Ended December 31, 2021 2020 2019 Common stock options 2,486,511 1,869,507 1,550,662 Restricted Stock 875 29,166 150,909 Convertible Debentures — — 1,742,500 2,487,386 1,898,673 3,444,071 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested.

Allowance for Doubtful Accounts

Allowance for Doubtful Accounts	12 Months Ended
	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Allowance for Doubtful Accounts	Note 7 – Allowance for Doubtful Accounts The rollforward of the Company’s allowance for doubtful accounts for the years ended December 31 is as follows (in thousands): 2021 2020 2019 Balance at beginning of period $ 111 $ 136 $ 177 Additions charged to costs and expenses 167 94 62 Reductions (10 ) (119 ) (103 ) Balance at end of period $ 268 $ 111 $ 136

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Note 8 – Inventories Inventory balances at December 31, 2021 and 2020 were as follows (in thousands): December 31, 2021 December 31, 2020 Raw materials $ 2,962 $ 1,538 Work in process 173 76 Finished Goods 1,279 1,774 Inventory Gross 4,414 3,388 Inventory Reserve (243 ) (244 ) Inventory Net $ 4,171 $ 3,144

Goodwill and Intangible assets

Goodwill and Intangible assets	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible assets	Note 9 – Goodwill and Intangible assets At December 31, 2021 and 2020, all of the Company’s goodwill of $8,362,000 is allocated to its Detection reporting. There were no additions, impairments or other changes to the Company’s goodwill balance for either of the years ended December 31, 2021 or 2020. Amortization expense related to intangible assets was approximately $230,000, $309,000 and $377,000 for the years ended December 31, 2021, 2020, and 2019, respectively. 2021 2020 2019 Weighted Gross Carrying Amount Patents and licenses $ 619 $ 595 $ 581 5 years Technology 8,257 8,257 8,257 10 years Customer relationships 272 272 272 7 years Tradename 259 259 259 10 years Total amortizable intangible assets 9,407 9,383 9,369 Accumulated Amortization Patents and licenses $ 534 $ 529 $ 520 Technology 7,769 7,571 7,299 Customer relationships 162 135 108 Tradename 259 259 259 Total accumulated amortization 8,724 8,494 8,186 Total amortizable intangible assets, net $ 683 $ 889 $ 1,183 Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated amortization expense 2022 217 2023 186 2024 103 2025 103 2026 74 $ 683

Accrued and Other Expenses

Accrued and Other Expenses	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued and Other Expenses	Note 10 – Accrued and Other expenses Accrued and other expenses consist of the following at December 31 (in thousands): 2021 2020 Accrued salary and related expenses $ 2,016 $ 3,654 Accrued accounts payable 2,838 2,405 Accrued professional fees 497 598 Other accrued expenses 291 382 $ 5,642 $ 7,039

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Leases	Note 11 – The Company has leases for office space and office equipment. The leases expire at various dates through 2024. In connection with the 2019 lease amendment for the Nashua headquarters, the Company was eligible for $110,160 of lease incentives. During 2021 the leasehold improvements were completed and the Company received the related lease incentives in cash resulting in an increase to the lease payable. In October 2021, the Company extended the term of its Nashua warehouse until 2024. This resulted in an increase of approximately $79,000 to the Company’s right of use asset and related lease liability. Year Ended December 31, Lease Cost Classification 2021 2020 Operating lease cost - Right of Use Operating expenses $ 862 $ 884 Operating lease cost - Variable Costs Operating expenses 186 165 Total $ 1,048 $ 1,049 Year Ended December 31, 2021 2020 Cash paid for operating cash flows from operating leases $ 919 $ 909 As of December 31, 2021 2020 Weighted-average remaining lease term of operating leases (in years) 1.33 2.21 Weighted-average discount rate for operating leases 5.5 % 5.6 % Maturities of the Company’s lease liabilities as of December 31, 2021 were as follows (in thousands): Year Ended December 31: Total 2022 931 2023 253 2024 16 Total lease payments 1,200 Less: imputed interest (45 ) Total lease liabilities 1,155 Less: current portion of lease liabilities (889 ) Long-term $ 266

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Federal Home Loan Banks [Abstract]
Stockholders' Equity	Note 12 – Stockholders’ Equity (a) Financing Activity On April 27, 2020, the Company issued 1,562,500 shares of common stock to several institutional investors at a price of $8.00 per share in a registered direct offering. The gross proceeds of the offering were approximately $12.5 million, and the Company received net proceeds of approximately $12.3 million. The Company also entered into an at-the-market d On March 2, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as representative of the several underwriters (the “Underwriters”), in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock, at a public offering price of $18.00 per share (the “Offering”). The Underwriting Agreement contained (b) Stock Options The Company has two effective stock option or stock incentive plans, the 2012 Stock Incentive Plan (the “2012 Plan”) and the 2016 Stock Incentive Plan (the “2016 Plan”) (collectively the “Stock Plans”). Each of the Stock Plans provide for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. All awards granted under the Stock Plans are required to be granted at not less than 100% of the fair market value of the related award on the respective grant date. Awards under the Stock Plans may be granted to employees, directors and advisors to the Company and its subsidiaries. At December 31, 2021, there were 37,871 shares available for issuance under the 2012 Plan. At the Company’s 2021 annual meeting, the 2016 Plan was amended to increase the number of shares of common stock available thereunder from 2,600,000 to 4,700,000. At December 31 , 2021 , there were 1,718,200 shares available for issuance under the 2016 Plan. Number of Weighted Average Weighted Average Outstanding, December 31, 2019 1,550,662 $ 4.33 Granted 563,502 $ 10.09 Exercised (155,149 ) $ 4.70 Forfeited (89,508 ) $ 2.51 Outstanding, December 31, 2020 1,869,507 $ 5.91 6.0 Years Granted 865,938 $ 16.33 Exercised (168,450 ) $ 6.10 Forfeited (80,484 ) $ 13.74 Outstanding, December 31, 2021 2,486,511 $ 9.27 5.42 Years Exercisable at December 31, 2019 881,461 $ 4.43 Exercisable at December 31, 2020 1,540,287 $ 5.55 Exercisable at December 31, 2021 1,619,855 $ 6.47 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 15 $ 30 $ 3 Engineering and product development 356 376 226 Marketing and sales 785 657 226 General and administrative expense 1,627 1,781 713 $ 2,783 $ 2,844 $ 1,168 As of December 31, 2021, there was approximately $4.3 million of total unrecognized compensation costs related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.7 years. Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Year Ended December 31, 2021 2020 2019 Average risk-free interest rate 0.42 % 0.65 % 1.88 % Expected dividend yield None None None Expected life 3.5 3.5 3.5 years Expected volatility 65.57-67.4 2 50.17-66.04 % 50.01% to 54.23 % Weighted average fair value $ $4.37 $2.34 The Company’s 2021, 2020 and 2019 average expected volatility and average expected life is based on zero-coupon Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Intrinsic value of stock options Year Ended December 31, 2021 2020 2019 Outstanding $ 3,820 $ 13,626 $ 5,465 Exercisable $ 3,730 $ 11,786 $ 3,067 Exercised $ 1,453 $ 1,037 $ 509 Company’s stock price at December 31 $ 7.20 $ 13.20 $ 7.77 (c) Restricted Stock The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. All of the Company’s restricted stock grants in 2021 and 2019 had time-based vesting requirements. The grant date fair value for restricted stock awards is based on the quoted market value of Company stock on the grant date. A summary of unvested restricted stock activity for the Stock Plans is follows: Year Ended December 31, 2021 2020 2019 Beginning outstanding balance 29,166 150,909 423,202 Granted 22,488 — 15,990 Vested (50,779 ) (118,077 ) (197,730 ) Forfeited — (3,666 ) (90,553 ) Ending outstanding balance 875 29,166 150,909 (d) Employee Stock Purchase Program: In December 2019, the Company’s Board of Directors adopted, and the stockholders approved the 2019 Employee Stock Purchase Plan (“ESPP”), effective January 1, 2020. The ESPP provides for the issuance of up 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board of Directors at any time. Certain amendments to the ESPP require stockholder approval. Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is ineligible to participate in the ESPP. Any eligible employee can enroll in the Plan as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. The Company issued 24,786 and 42,606 shares of common stock under the ESPP for the years ended December 31, 2021 and 2020, respectively. 882,608 shares of Company common stock are reserved for issuance under the ESPP as of December 31, 2021.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes Income Taxes The components of income tax expense for the years ended December 31 are as follows (in thousands): 2021 2020 2019 Current provision: Federal $ — $ — $ — State — 37 42 Foreign — — — $ — $ 37 $ 42 Deferred provision: Federal $ 1 $ 1 $ 1 State — — — Foreign — — — $ 1 $ 1 $ 1 Total $ 1 $ 38 $ 43 The Company adopted ASU 2019-12 as non-income non-income ASU 2019-12. A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31 is as follows: 2021 2020 2019 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 5.2 % 2.4 % 1.7 % Net state impact of deferred rate change 0.8 % (0.7 %) (0.2 %) Stock compensation expense 1.3 % 0.9 % (10.7 %) Other permanent differences (0.1 %) (0.1 %) 0.0 % Change in valuation allowance (24.4 %) (13.4 %) (6.0 %) Tax credits 3.1 % 1.4 % 2.8 % Accrual to TR (1.4 %) 0.0 % 1.3 % FV Mark to market on convertible notes 0.0 % (9.0 %) (10.4 %) Foreign Rate Differential 0.0 % 0.0 % 0.2 % True Ups - NOL Expiration/162(m) limits (5.4 %) (2.8 %) 0.0 % Effective income tax 0.1 % (0.3 %) (0.3 %) Deferred tax assets and liabilities are recognized for the expected future tax consequences of net operating loss carryforwards, tax credit carryforwards and temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that the deferred tax assets will not be realized. Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. The Company has fully reserved the net deferred tax assets, as it is more likely than not that the deferred tax assets will not be utilized. Deferred tax assets (liabilities) are composed of the following at December 31, 2021 and 2020 (in thousands): 2021 2020 Inventory (Section 263A) $ 276 $ 248 Inventory reserves 61 60 Receivable reserves 67 28 Other accruals 854 1,081 Deferred revenue 107 75 Accumulated depreciation/amortization 8 37 Stock options 795 459 Developed technology 1,242 1,449 Tax credits 4,176 3,859 NOL carryforward 38,383 36,078 Lease Liability 290 415 Deferred tax assets 46,259 43,789 Valuation allowance (45,994 ) (43,356 ) Right of Use Asset (265 ) (433 ) Goodwill tax amortization (5 ) (4 ) Deferred tax liability $ (5 ) $ (4 ) The increase in the net deferred tax assets and corresponding valuation allowance during the As of December 31, 2021, the Company has federal net operating loss carryforwards totaling approximately $159.0 million. Federal net operating loss carryforwards totaling $120.1 million will expire at various dates from 2022 and 2037. The remaining $39.0 million of the federal net operating losses generated since December 31, 2017 can be carried forward indefinitely. As of December 31, 2021, the Company has provided a valuation allowance for its net operating loss carryforwards due to the uncertainty of the Company’s ability to generate sufficient taxable income in future years to obtain the benefit from the utilization of the net operating loss carryforwards. In the event of a deemed change in control, an annual limitation imposed on the utilization of the net operating losses may result in the expiration of all or a portion of the net operating loss carryforwards. There were no net operating losses utilized for the years ended December 31, 2021, 2020, or 2019. The Company currently has approximately $5.2 million in net operating losses that are subject to limitations related to Xoft. Approximately $656,000 can be used annually through 2029. The Company has available tax credit carryforwards (adjusted to reflect provisions of the Tax Reform Act of 1986) to offset future income tax liabilities totaling approximately $4.2 million. The credits expire in various years through 2041. The Company has additional tax credits of $1.8 million related to Xoft which have been fully reserved for and as a result no deferred tax asset has been recorded. These credits expire in various years through 2030. ASC 740-10 de-recognition, As of December 31, 2021 and 2020, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. ended December 31, 2021, 2020 and 2019. The Company files United States federal and various state income tax returns. The Company also files tax returns in France. Generally, the Company’s three preceding tax years remain subject to examination by federal and state taxing authorities. The Company is not under examination by any other federal or state jurisdiction for any tax year. The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December 31, 2021 will significantly change within the next 12 months.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	Note 14 – Segment Reporting (a) Segment Reporting Operating segments are the components of our business for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision maker is our chief executive officer. Our operating segments are generally organized by the type of product or service offered and by geography. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Segment revenues: Detection $ 22,019 $ 21,997 $ 22,319 Therapy 11,619 7,701 9,021 Total Revenue $ 33,638 $ 29,698 $ 31,340 Segment gross profit: Detection $ 18,510 $ 17,856 $ 18,627 Therapy 5,733 3,498 5,600 Total gross profit $ 24,243 $ 21,354 $ 24,227 Segment operating income (loss): Detection $ 1,563 $ 2,719 $ 2,564 Therapy (1,835 ) (3,028 ) (1,476 ) Segment operating income (loss) $ (272 ) $ (309 ) $ 1,088 General administrative $ (10,460 ) $ (9,079 ) $ (7,486 ) Interest expense (141 ) (476 ) (784 ) Loss on extinguishment of debt (386 ) (341 ) — Other income 15 97 345 Fair value of convertible debentures — (7,464 ) (6,671 ) Loss before income tax $ (11,244 ) $ (17,572 ) $ (13,508 ) Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Detection depreciation and amortization Depreciation $ 123 $ 115 $ 103 Amortization $ 158 164 240 Therapy depreciation and amortization Depreciation $ 129 $ 124 $ 166 Amortization $ 73 128 128 (b) Geographic Information The Company’s sales are made to customers, distributors and dealers of mammography, electronic brachytherapy equipment and other medical equipment, and to foreign distributors of mammography and electronic brachytherapy equipment. Export revenue to a single country did not exceed 10% of total revenue in any year. Total export revenues As of December 31, 2021 and 2020, the Company had outstanding receivables of $3.3 million and $3.4 million, respectively, from distributors and customers of its products who are located outside of the U.S. Percent of Export sales Region 2021 2020 2019 Europe 39 % 45 % 57 % Taiwan 12 % 13 % 15 % Canada 3 % 5 % 7 % China 35 % 22 % 8 % Other 11 % 15 % 13 % Total 100 % 100 % 100 % Total Export Revenue $ 7,527 $ 6,081 $ 3,788 Significant export sales in Europe are as follows: Percent of Export sales Region 2021 2020 2019 France 47 % 41 % 34 % Spain 17 % 17 % 12 % Russia 8 % 0 % 0 % Switzerland 8 % 0 % 0 % Italy 5 % 8 % 2 % Germany 4 % 12 % 4 % United Kingdom 4 % 6 % 2 % (c) Major Customers The Company had one major OEM customer, GE Healthcare, with revenues of approximately $4.8 million in 2021, $5.0 million in 2020 and $7.6 million in 2019 or 14%, 17% and 24% of total revenue, respectively. Cancer detection products are also sold through OEM partners, including GE Healthcare, Fujifilm Medical Systems, Siemens Medical, and Vital Images. For the year ended December 31, 2021, these four OEM partners composed approximately 29% of Detection revenues and 19% of total revenue. Detection OEM partners in total composed approximately 40% of Detection revenue and 26% of total revenue for the year ended December 31, 202 1 OEM partners represented $5.5 million or 60% of outstanding receivables as of December 31, 2021, with GE Healthcare accounting for $.7 million or 8% of this amount. The four largest Therapy customers composed 2.8 million or 31% of outstanding receivables as of December 31, 2021. The largest Detection direct customer represents $.3 million or 3% of outstanding receivables as of December 31, 2021. These customers in total represented $8.6 million or 94% of outstanding receivables as of December 31, 2021.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies (a) Purchase Commitments The Company has non-cancelable (b) Employment Agreements The Company has entered into employment agreements with certain key current and former executives. The employment agreements provide for minimum annual salaries and performance-based annual bonus compensation as defined in their respective agreements. In addition, the employment agreements provide that if employment is terminated without cause, the executive will receive an amount equal to their respective base salary then in effect for (i) fifteen months from the date of termination, for Mr. Klein, CEO, (ii) eighteen months from the date of termination, for Ms. Stevens, President, and (iii) twelve months from the date of termination, for Mr. Carter, CFO, and in each case, plus the pro rata portion of any annual bonus earned in any employment year through the date of termination. (c) Royalty Obligations In connection with prior litigation, the Company received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete non-compete (d) Legal Matters In December 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation (the “Asset Purchase Agreement”). In accordance with the Asset Purchase Agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction on January 30, 2017 less a holdback reserve of $350,000 for net proceeds of approximately $2.9 million. On September 5, 2018, third-party Yeda Research and Development Company Ltd. (“Yeda”), filed a complaint (the “Complaint”) against the Company and Invivo in the United States District Court for the Southern District of New York, captioned Yeda Research and Development Company Ltd. v. iCAD, Inc. and Invivo Corporation, Case No. 1:18-cv-08083-GBD, related to the Company’s sale of the VersaVue software and DynaCAD product under the Asset Purchase Agreement. Yeda alleged, among other things, that the Company infringed upon Yeda’s source code, which was originally licensed to the Company, by using it in the products that the Company sold to Invivo and that it is entitled to damages that could include, among other things, profits relating to the sales of these products. On April , , the Company and Yeda entered into a Settlement and Release Agreement (the “Settlement Agreement”) whereby the Company furnished to Yeda a one-time cash payment of $ and received a full, non-conditional release from Yeda of any and all claims related to the Complaint and the subject of the Complaint. Neither the Company nor Invivo acknowledged any wrongdoing at any point in connection with the Complaint or the subject matter thereof. The Escrowed Amount was reserved, in part, to cover any legal expenses related to the Asset Purchase Agreement and the transactions contemplated therein. The remaining balance of the Escrowed Amount following such expenses is due and payable to the Company in accordance with the terms of the Asset Purchase Agreement. The Company and Invivo agreed that Invivo would pay $ of the Escrowed Amount and the Company expensed approximately $ in the second quarter of . In addition to the foregoing, the Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations, other than as set forth above. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. The Company may be party to certain actions that have been filed against the Company which are being vigorously defended. The Company has determined that potential losses in these matters are neither probable or reasonably possible at this time. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 16 – Notes Payable (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 under and terminated the Loan Agreement with the Bank, and its collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. (b) Loan and Security Agreement – Silicon Valley Bank On August 7, 2017, the Company entered into a Loan and Security Agreement, (as amended, the “SVB Loan Agreement”), with Silicon Valley Bank that provided an initial term loan facility of $6.0 million and a $4.0 million revolving line of credit. On March 30, 2020, the Company elected to repay all outstanding obligations (including accrued interest) and retire the SVB Loan Agreement. The Company accounted for this repayment and retirement as an extinguishment of the SVB Loan Agreement. In addition to the outstanding principal and accrued interest, the Company was required to pay the $ final payment, a termination fee of $ and other costs totaling $ . The Company also wrote off unamortized original closing costs as of the extinguishment date. In the Company recorded a loss on extinguishment of approximately $ related to the repayment and retirement of the SVB Loan Agreement. The loss on extinguishment was composed of approximately $ for the unaccrued final payment, $ termination fee, and $ of unamortized and other closing costs. (c) Convertible Debentures On December 20, 2018, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional and accredited investors (the “Investors”), including, but not limited to, all directors and executive officers of the Company at the time, pursuant to which the Investors purchased unsecured subordinated convertible debentures (the “Convertible Debentures”) with an aggregate principal amount of approximately $7.0 million in a private placement. On February 21, 2020 (the “Conversion Date”), the conditions permitting a forced conversion were met, and the Company elected to exercise its forced conversion right under the terms of the Convertible Debentures. As a result of this election, all of the outstanding Convertible Debentures were converted, at a conversion price of $4.00 per share, into 1,742,500 shares of the Company’s common stock. In accordance with the make-whole provisions in the Convertible Debentures, the Company also issued an additional 76,966 shares of its common stock. The make-whole amount represented the total interest which would have accrued through the maturity date of the Convertible Debentures, less the amounts previously paid, totaling $697,000. The conversion prices related to the make-whole amount were dependent on whether the Investors were related parties or unrelated third parties. Accounting Considerations and Fair Value Measurements Related to the Convertible Debentures The Company had previously elected to make a one-time, irrevocable The Company recorded a final adjustment to the Convertible Debentures based on their fair value on the Conversion Date, just prior to the forced conversion being completed. Given that the Company’s prior simulation model included the assumption that the Company would elect to force conversion in 100% of scenarios when the requirements were met, the final valuation was based on the actual results of the forced conversion. As such, the Company based the final fair value adjustment to the Convertible Debentures just prior to conversion on the number of shares of common stock that were issued to the Investors upon conversion and the fair value of the Company’s common stock as of the Conversion Date. Company Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 Probability of default event 0.45 % N/A 1 100.00 % 100.00 % 1 100.00 % N/A 1 18.52 % N/A 1 Represents Note 4 - Fair Value Measurements, below. The Company’s stock price is based on the closing stock price on the valuation date. The conversion price is based on the contractual conversion price included in the SPA. The remaining term was determined based on the remaining time period to maturity of the Convertible Debentures. The Company’s equity volatility estimate was based on the Company’s historical equity volatility, the Company’s implied and observed volatility of option pricing, and the historical equity and observed volatility of option pricing for a selection of comparable guideline public companies. The risk-free rate was determined based on U.S. Treasury securities with similar terms. The probability of the occurrence of a default event was based on Bloomberg’s one year estimate of default risk for the Company (extrapolated over the remaining term). The utilization of the Forced Conversion right and the default redemption right is based on management’s best estimate of both features being exercised upon the occurrence of the related contingent events. The effective discount rate utilized at the December 31, 2019 and February 21, 2020 valuation dates was solved for utilizing the simulation model based on the principal value of the Convertible Debentures, as the transaction was determined to represent an ‘arm’s length’ transaction. The effective discount was corroborated against market yield data which implied the Company’s credit rating, and this implied credit rating will be utilized to determine the changes in the effective discount rate at future valuation dates. The effective discount rate utilized at the December 31, 2019 valuation date was based on yields on CCC-rated The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970 The Company recorded a loss from the change in fair value of the Convertible Debentures of approximately $7.5 million for the year ending December 31 , 2020 . Upon the consummation of the forced conversion, the Company issued 1,816,466 shares of common stock with a fair value of approximately $21.2 million, which was reclassified to stockholders’ equity.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2021
Employee Benefit Plan [Abstract]
Employee Benefit Plan	Note 17 – Employee Benefit Plan The Company has a 401(k) retirement plan (the “401(k) Plan”) for the benefit of eligible employees, as defined. Each participant may elect to contribute up to 90% of his or her compensation to the 401(k) Plan each year, subject to certain Internal Revenue Service limitations. The Company makes a safe harbor matching contribution of 100% of every dollar contributed, not to exceed 3% of participants’ eligible wages. The Company contributed approximately $.5 million during each of the years ended December 31, 2021 and 2020, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events The Company has evaluated events and transactions subsequent to the balance sheet date to the date of filing and is not aware of any events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities.
Risk and Uncertainty	Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 return to prior levels. The COVID-19 COVID-19 COVID-19; March 2022 COVID-19 Although the Company did not see any material impact to trade accounts receivable losses in the year ended December 31, 2021, the Company’s exposure may increase if its customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 COVID-19
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, and iCAD France, LLC. All material inter-company transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less and which are unrestricted as to timing or method of withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000 per depositor. Historically, the Company has not experienced any losses related to these balances
Financial instruments	Financial instruments Financial instruments consist of cash and cash equivalents, trade accounts receivable, contract assets, accounts payable, accrued and other expenses and notes payable. Due to their short-term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2021 and 2020.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are initially established through a process of reviewing the financial history and stability of each customer and the Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. Included in accounts receivable at December 31, 2021 are unbilled receivables of approximately $0.4 million which are scheduled t o The Company’s policy is to maintain allowances for potential losses resulting from the inability of a portion of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its allowance for doubtful accounts. An amount is written off against the allowance after all attempts to collect the receivable have failed.
Inventory	Inventory The Company uses the first-in, first-out The
Property and Equipment	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which is generally three
Goodwill	Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles—Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of Goodwill, include the following: • significant and sustained underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the Company’s assets in the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant and sustained decline in the Company’s stock price; and • a decline in the Company’s market capitalization below net book value. The two reporting units within iCAD are its segments, Detection and Therapy. The Company records an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. When the Company evaluates potential impairments outside of its annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. Fair values for the reporting units are based on a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company uses internal forecasts to estimate future cash flows and includes estimates of long-term future growth rates based on our most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in our forecasts. Discount rates are derived from a capital asset pricing model and by analyzing published rates for industries relevant to our reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in our internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as the fact that market data may not be available for divisions within larger conglomerates or non-public The Company corroborates the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to our business profile, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. Equally important, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company assesses each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weights the methodologies appropriately. The Company performed the annual impairment assessment at October 1, 2021 and compared the fair value of each reporting unit to its carrying value as of this date. The fair value of the Detection reporting unit exceeded the carrying value. Accordingly, impairment of goodwill was recorded. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities, to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment.
Long Lived Assets	Long Lived Assets In accordance with FASB ASC Topic 360 , “Property, Plant an d Equipment” (“ASC 360 ”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360 -10 -35 uses “events and circumstances” criteria to determine when, if at all, an asset (or asset group) is evaluated for recoverability. Thus, there is no set interval or frequency for recoverability evaluation. In accordance with ASC 360 -10 -35 -21 the following factors are examples of events or changes in circumstances that indicate t h • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). In accordance with ASC 360-10-35-17, The Company did record any impairment charges on its long-lived assets for the years ended December , or December , . Intangible assets subject to amortization consist primarily of patents, technology intangibles, trade names, customer relationships and distribution agreements purchased in the Company’s previous acquisitions. These assets are amortized on a straight-line basis or the pattern of economic benefit over their estimated useful lives of 5 to 10 years.
Leases	Leases Per ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is an operating or financing contract, or part of a contract, that conveys the right to control the use of an identified tangible asset for a period of time in exchange for consideration. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement right-of-use Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease
Stock-Based Compensation	Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company grants to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows ASC 718, “Compensation – Stock Compensation” re-measured The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, and the number of options that will be forfeited prior to the completion of their vesting requirements. The Company estimates forfeitures based on historical experience with pre-vested
Revenue Recognition	Revenue Recognition In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services and the amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. The Company applies the following five steps to guide revenue recognition: 1) Identify the contract(s) with a customer 2) Identify the performance obligations in the contract 3) Determine the transaction price , 4) Allocate the transaction price to the performance obligations in the contract that performance obligation or to a distinct good or service that forms part of a performance obligation. The Company determines SSP based on the price at which the performance obligation is sold separately. If the SSP is not observable through past transactions, the Company estimates the SSP taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. 5) Recognize revenue when (or as) the Company satisfies a performance obligation The Company recognizes revenue from its contracts with customers primarily from the sale of products and from the sale of services and supplies. Revenue is recognized when control of the promised goods or services is transferred to a customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. For iCAD’s typical product revenue, control typically transfers upon shipment as title and risk of loss have passed to the customer. Services and supplies are considered to be transferred as the services are performed or over the term of the service or supply agreement. The Company enters into contracts that can include various combinations of products and services, which are generally capable of being distinct and accounted for as separate performance obligations. Perpetual software license are accounted for as a single performance obligation and revenue is recognized at the point in time when ownership is transferred to the customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of revenue. The Company continues to provide for estimated warranty costs on original product warranties at the time of sale. Goods and Services Classifications Products . Product revenue consists of sales of cancer detection perpetual licenses, cancer therapy systems, cancer therapy applicators, cancer therapy disposable applicators and other accessories that are typically shipped with a cancer therapy system. The Company transfers control and recognizes a sale when the product is shipped from the manufacturing or warehousing facility to the customer. Service Contracts 12 48 Supply and Source Usage Agreements . Revenue from supply and source usage agreements is recognized on a straight-line basis over the term of the supply or source agreement. Professional Services . Revenue from fixed fee service contracts is recognized on a straight-line basis over the term of the agreement. Revenue from professional service contracts entered into with customers on a time and materials basis is recognized over the term of the agreement in proportion to the costs incurred in satisfying the obligations under the contract. Other . Other revenue consists primarily of miscellaneous products and services. The Company transfers control and recognizes a sale when the installation services are performed or when the Company ships the product from the Company’s manufacturing or warehouse facility to the customer. Significant Judgments The Company’s contracts with customers may include promises to transfer multiple products and services to a customer and identifying distinct performance obligations that should be accounted for separately versus together may require significant judgment. For arrangements with multiple performance obligations, the Company allocates revenue to each performance obligation based on its relative standalone selling price. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company generally determines standalone selling prices based on the prices charged to customers and uses a range of amounts to estimate standalone selling prices when the Company sells each of the products and services separately and need to determine whether there is a discount that needs to be allocated based on the relative standalone selling prices of the various products and services. The Company typically has more than one range of standalone selling prices for individual products and services due to the stratification of those products and services by customers and circumstances. In these instances, the Company may use information such as the type of customer and geographic region in determining the range of standalone selling prices. The Company may provide credits or incentives to customers, which are accounted for as variable consideration when estimating the transaction price of the contract and amounts of revenue to recognize. The amount of variable consideration to include in the transaction price is estimated at contract inception using either the estimated value method or the most likely amount method based on the nature of the variable consideration. These estimates are updated at the end of each reporting period as additional information becomes available and revenue is recognized only to the extent that it is probable that a significant reversal of any amounts of variable consideration included in the transaction price will not occur. The Company provides for estimated warranty costs on original product warranties at the time of sale. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes incremental costs of obtaining a contract with a customer as an asset if the Company expects the benefit of those costs to be longer than one year and as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one year or less. Right to Invoice Where applicable, the Company recognizes revenue from a contract with a customer in an amount that corresponds directly with the value to the customer of the Company’s performance completed to date and the amount to which the Company has a right to invoice. Sales and Other Similar Taxes The Company excludes sales taxes and similar taxes from the measurement of transaction price and ensures compliance w Significant Financing Component The Company does not adjust the promised amount of consideration for the effects of a significant financing component if the Company expects, at contract inception, that the period between when the entity transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or less. Promised Goods or Services that are Immaterial in the Context of a Contract The Company assesses materiality of promised goods or services as performance obligations in the context of a contract and the Company does not aggregate and assess immaterial items at the entity level. When determining whether a good or service is immaterial in the context of a contract, the assessment will be made based on the application of ASC 606 at the contract level. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which it recognizes revenue at the amount to which it has the right to invoice for services performed.
Cost of Revenue	Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house
Warranty Costs	Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty costs have not historically been material to the Company’s consolidated financial statements.
Engineering and Product Development Costs	Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials are expensed as incurred.
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2021, 2020 and 2019 was approximately $689,000, $274,000, and $1,101,000, respectively.
Income Taxes	Income Taxes The Company follows the liability method under ASC Topic 740 “ Income Taxes

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousand): Fair Value Measurements (in thousands) as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 — — $ 30,573 Total Assets $ 30,573 — — $ 30,573 Fair Value Measurements (in thousands) as of December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 24,635 $ — $ — $ 24,635 Total Assets $ 24,635 $ — $ — $ 24,635
Schedule of Reconciliation of Changes In Fair Value of Convertible Debentures	The following is a roll forward of the Company’s Level 3 instruments for the years ended December 31, 2021 and 2020: Convertible Debentures Balance, December 31, 2019 $ 13,642 Issuances — Fair value adjustments 7,522 Conversion (21,164 ) Balance, December 31, 2020 $ —

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments	The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition and sales channel, reconciled to its reportable segments (in thousands). Year ended December 31, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 15,661 $ 7,924 $ 23,585 Service contracts 6,358 1,517 7,875 Supply and source usage agreements — 2,089 2,089 Professional services — 89 89 $ 22,019 $ 11,619 $ 33,638 Timing of Revenue Recognition Goods transferred at a point in time $ 15,584 $ 8,012 $ 23,596 Services transferred over time 6,435 3,607 10,042 $ 22,019 $ 11,619 $ 33,638 Sales Channels Direct sales force $ 14,713 $ 4,421 $ 19,134 OEM partners 7,306 — 7,306 Channel partners — 7,198 7,198 $ 22,019 $ 11,619 $ 33,638 Year ended December 31, 2020 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,291 $ 4,535 $ 20,826 Service contracts 5,661 1,333 6,994 Supply and source usage agreements — 1,804 1,804 Professional services — 29 29 Other 45 — 45 $ 21,997 $ 7,701 $ 29,698 Timing of Revenue Recognition Goods transferred at a point in time $ 16,332 $ 4,624 $ 20,956 Services transferred over time 5,665 3,077 8,742 $ 21,997 $ 7,701 $ 29,698 Sales Channels Direct sales force $ 13,809 $ 3,773 $ 17,582 OEM partners 8,188 — 8,188 Channel partners — 3,928 3,928 $ 21,997 $ 7,701 $ 29,698 Year ended December 31, 2019 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 16,788 $ 4,957 $ 21,745 Service contracts 5,370 1,814 7,184 Supply and source usage agreements — 2,036 2,036 Professional services — 153 153 Other 161 61 222 $ 22,319 $ 9,021 $ 31,340 Timing of Revenue Recognition Goods transferred at a point in time $ 16,949 $ 5,391 $ 22,340 Services transferred over time 5,370 3,630 9,000 $ 22,319 $ 9,021 $ 31,340 Sales Channels Direct sales $ 11,968 $ 5,804 $ 17,772 OEM partners 10,351 — 10,351 Channel partners — 3,217 3,217 $ 22,319 $ 9,021 $ 31,340
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers	The following table provides information about receivables, current and non-current Balance at Balance at Receivables, which are included in ‘Trade accounts receivable’ $ 8,891 $ 10,027 Current contract assets, which are included in “Prepaid and other assets” $ 1,895 $ 481 Non-current $ 844 $ 1,434 Contract liabilities, which are included in “Deferred revenue” $ 6,093 $ 6,384
Summary of Changes in Deferred Revenue	Changes in deferred revenue from contracts with customers were as follows (in thousands): Year Ended Year Ended Balance at beginning of period $ 6,384 $ 5,604 Deferral of revenue 12,315 11,212 Recognition of deferred revenue (12,606 ) (10,432 ) Balance at end of period $ 6,093 $ 6,384
Schedule of Changes of Capitalized Costs to Obtain Contract	Changes in the balance of capitalized costs to obtain a contract were as follows (in thousands): Years Ended December 31, 2021 2020 Balance at beginning of period $ 406 $ 379 Deferral of costs to obtain a contract 249 157 Recognition of costs to obtain a contract (353 ) (130 ) Balance at end of period $ 302 $ 406

Net Loss per Common Share (1o)

Net Loss per Common Share (1o) (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2021 2020 2019 Net loss available to common shareholders $ (11,245 ) $ (17,610 ) $ (13,551 ) Basic shares used in the calculation of earnings per share 24,778 22,140 18,378 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 24,778 22,140 18,378 Net loss per share Basic $ (0.45 ) $ (0.80 ) $ (0.74 ) Diluted $ (0.45 ) $ (0.80 ) $ (0.74 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The following table summarizes the number of shares of common stock for convertible securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: Year Ended December 31, 2021 2020 2019 Common stock options 2,486,511 1,869,507 1,550,662 Restricted Stock 875 29,166 150,909 Convertible Debentures — — 1,742,500 2,487,386 1,898,673 3,444,071

Allowance for Doubtful Accoun_2

Allowance for Doubtful Accounts (Tables)	12 Months Ended
	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	The rollforward of the Company’s allowance for doubtful accounts for the years ended December 31 is as follows (in thousands): 2021 2020 2019 Balance at beginning of period $ 111 $ 136 $ 177 Additions charged to costs and expenses 167 94 62 Reductions (10 ) (119 ) (103 ) Balance at end of period $ 268 $ 111 $ 136

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Current Inventory	Inventory balances at December 31, 2021 and 2020 were as follows (in thousands): December 31, 2021 December 31, 2020 Raw materials $ 2,962 $ 1,538 Work in process 173 76 Finished Goods 1,279 1,774 Inventory Gross 4,414 3,388 Inventory Reserve (243 ) (244 ) Inventory Net $ 4,171 $ 3,144

Goodwill and Intangible assets

Goodwill and Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	2021 2020 2019 Weighted Gross Carrying Amount Patents and licenses $ 619 $ 595 $ 581 5 years Technology 8,257 8,257 8,257 10 years Customer relationships 272 272 272 7 years Tradename 259 259 259 10 years Total amortizable intangible assets 9,407 9,383 9,369 Accumulated Amortization Patents and licenses $ 534 $ 529 $ 520 Technology 7,769 7,571 7,299 Customer relationships 162 135 108 Tradename 259 259 259 Total accumulated amortization 8,724 8,494 8,186 Total amortizable intangible assets, net $ 683 $ 889 $ 1,183
Schedule of Expected Amortization Expense	Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated amortization expense 2022 217 2023 186 2024 103 2025 103 2026 74 $ 683

Accrued and Other Expenses (Tab

Accrued and Other Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued and Other Expenses	Accrued and other expenses consist of the following at December 31 (in thousands): 2021 2020 Accrued salary and related expenses $ 2,016 $ 3,654 Accrued accounts payable 2,838 2,405 Accrued professional fees 497 598 Other accrued expenses 291 382 $ 5,642 $ 7,039

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	Year Ended December 31, Lease Cost Classification 2021 2020 Operating lease cost - Right of Use Operating expenses $ 862 $ 884 Operating lease cost - Variable Costs Operating expenses 186 165 Total $ 1,048 $ 1,049 Year Ended December 31, 2021 2020 Cash paid for operating cash flows from operating leases $ 919 $ 909 As of December 31, 2021 2020 Weighted-average remaining lease term of operating leases (in years) 1.33 2.21 Weighted-average discount rate for operating leases 5.5 % 5.6 %
Summary of Detained Information of Lease Liabilities	Maturities of the Company’s lease liabilities as of December 31, 2021 were as follows (in thousands): Year Ended December 31: Total 2022 931 2023 253 2024 16 Total lease payments 1,200 Less: imputed interest (45 ) Total lease liabilities 1,155 Less: current portion of lease liabilities (889 ) Long-term $ 266

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Federal Home Loan Banks [Abstract]
Summary of Stock Option Activity for all Stock Option Plans	Number of Weighted Average Weighted Average Outstanding, December 31, 2019 1,550,662 $ 4.33 Granted 563,502 $ 10.09 Exercised (155,149 ) $ 4.70 Forfeited (89,508 ) $ 2.51 Outstanding, December 31, 2020 1,869,507 $ 5.91 6.0 Years Granted 865,938 $ 16.33 Exercised (168,450 ) $ 6.10 Forfeited (80,484 ) $ 13.74 Outstanding, December 31, 2021 2,486,511 $ 9.27 5.42 Years Exercisable at December 31, 2019 881,461 $ 4.43 Exercisable at December 31, 2020 1,540,287 $ 5.55 Exercisable at December 31, 2021 1,619,855 $ 6.47
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Year Ended December 31, 2021 2020 2019 Cost of revenue $ 15 $ 30 $ 3 Engineering and product development 356 376 226 Marketing and sales 785 657 226 General and administrative expense 1,627 1,781 713 $ 2,783 $ 2,844 $ 1,168
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Year Ended December 31, 2021 2020 2019 Average risk-free interest rate 0.42 % 0.65 % 1.88 % Expected dividend yield None None None Expected life 3.5 3.5 3.5 years Expected volatility 65.57-67.4 2 50.17-66.04 % 50.01% to 54.23 % Weighted average fair value $ $4.37 $2.34
Summary Of Intrinsic Values Of Option And Closing Market Price	Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Intrinsic value of stock options Year Ended December 31, 2021 2020 2019 Outstanding $ 3,820 $ 13,626 $ 5,465 Exercisable $ 3,730 $ 11,786 $ 3,067 Exercised $ 1,453 $ 1,037 $ 509 Company’s stock price at December 31 $ 7.20 $ 13.20 $ 7.77
Summary of Restricted Stock Activity for All Equity Incentive Plans	A summary of unvested restricted stock activity for the Stock Plans is follows: Year Ended December 31, 2021 2020 2019 Beginning outstanding balance 29,166 150,909 423,202 Granted 22,488 — 15,990 Vested (50,779 ) (118,077 ) (197,730 ) Forfeited — (3,666 ) (90,553 ) Ending outstanding balance 875 29,166 150,909

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense for the years ended December 31 are as follows (in thousands): 2021 2020 2019 Current provision: Federal $ — $ — $ — State — 37 42 Foreign — — — $ — $ 37 $ 42 Deferred provision: Federal $ 1 $ 1 $ 1 State — — — Foreign — — — $ 1 $ 1 $ 1 Total $ 1 $ 38 $ 43
Summary of Effective and the Federal Statutory Income Tax Rate	A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31 is as follows: 2021 2020 2019 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 5.2 % 2.4 % 1.7 % Net state impact of deferred rate change 0.8 % (0.7 %) (0.2 %) Stock compensation expense 1.3 % 0.9 % (10.7 %) Other permanent differences (0.1 %) (0.1 %) 0.0 % Change in valuation allowance (24.4 %) (13.4 %) (6.0 %) Tax credits 3.1 % 1.4 % 2.8 % Accrual to TR (1.4 %) 0.0 % 1.3 % FV Mark to market on convertible notes 0.0 % (9.0 %) (10.4 %) Foreign Rate Differential 0.0 % 0.0 % 0.2 % True Ups - NOL Expiration/162(m) limits (5.4 %) (2.8 %) 0.0 % Effective income tax 0.1 % (0.3 %) (0.3 %)
Deferred Tax Assets (Liabilities)	The Company has fully reserved the net deferred tax assets, as it is more likely than not that the deferred tax assets will not be utilized. Deferred tax assets (liabilities) are composed of the following at December 31, 2021 and 2020 (in thousands): 2021 2020 Inventory (Section 263A) $ 276 $ 248 Inventory reserves 61 60 Receivable reserves 67 28 Other accruals 854 1,081 Deferred revenue 107 75 Accumulated depreciation/amortization 8 37 Stock options 795 459 Developed technology 1,242 1,449 Tax credits 4,176 3,859 NOL carryforward 38,383 36,078 Lease Liability 290 415 Deferred tax assets 46,259 43,789 Valuation allowance (45,994 ) (43,356 ) Right of Use Asset (265 ) (433 ) Goodwill tax amortization (5 ) (4 ) Deferred tax liability $ (5 ) $ (4 )

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Segment revenues: Detection $ 22,019 $ 21,997 $ 22,319 Therapy 11,619 7,701 9,021 Total Revenue $ 33,638 $ 29,698 $ 31,340 Segment gross profit: Detection $ 18,510 $ 17,856 $ 18,627 Therapy 5,733 3,498 5,600 Total gross profit $ 24,243 $ 21,354 $ 24,227 Segment operating income (loss): Detection $ 1,563 $ 2,719 $ 2,564 Therapy (1,835 ) (3,028 ) (1,476 ) Segment operating income (loss) $ (272 ) $ (309 ) $ 1,088 General administrative $ (10,460 ) $ (9,079 ) $ (7,486 ) Interest expense (141 ) (476 ) (784 ) Loss on extinguishment of debt (386 ) (341 ) — Other income 15 97 345 Fair value of convertible debentures — (7,464 ) (6,671 ) Loss before income tax $ (11,244 ) $ (17,572 ) $ (13,508 )
Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss)	Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Year Ended December 31, 2021 2020 2019 Detection depreciation and amortization Depreciation $ 123 $ 115 $ 103 Amortization $ 158 164 240 Therapy depreciation and amortization Depreciation $ 129 $ 124 $ 166 Amortization $ 73 128 128
Summary of Concentration of Revenue by Geographic Area	Percent of Export sales Region 2021 2020 2019 Europe 39 % 45 % 57 % Taiwan 12 % 13 % 15 % Canada 3 % 5 % 7 % China 35 % 22 % 8 % Other 11 % 15 % 13 % Total 100 % 100 % 100 % Total Export Revenue $ 7,527 $ 6,081 $ 3,788 Significant export sales in Europe are as follows: Percent of Export sales Region 2021 2020 2019 France 47 % 41 % 34 % Spain 17 % 17 % 12 % Russia 8 % 0 % 0 % Switzerland 8 % 0 % 0 % Italy 5 % 8 % 2 % Germany 4 % 12 % 4 % United Kingdom 4 % 6 % 2 %

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures	The Company Input December 31, 2019 February 21, 2020 Company’s stock price $ 7.77 $ 11.64 Conversion price 4.00 4.00 Remaining term (years) 1.97 0.00 Equity volatility 49.00 % N/A Risk free rate 1.57 % N/A 1 Probability of default event 0.45 % N/A 1 100.00 % 100.00 % 1 100.00 % N/A 1 18.52 % N/A 1 Represents Note 4 - Fair Value Measurements, below.
Schedule of Fair Value and Principal Value of Convertible Debentures	The fair value and principal value of the Convertible Debentures as of December 31, 2019 and the Conversion Date was as follows (in thousands): Convertible Debentures December 31, 2019 February 21, 2020 Fair value, in accordance with fair value option $ 13,642 $ 21,164 Principal value outstanding $ 6,970 $ 6,970

Organization and Business - Add

Organization and Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Operating Segments	2

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Oct. 01, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basis Of Presentation And Significant Accounting Policies [Line Items]
Maturity for cash and cash equivalents		90 days
Insurance coverage		$ 250,000
Goodwill impairment	$ 0	0	$ 0
Impairment charges on long lived assets
Product delivery period to customer		one year or less
Advertising expense		$ 689,000	$ 274,000	$ 1,101,000
Unbilled receivables		$ 400,000
Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets		10 years
Maximum [Member] | Leasehold Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Property and equipment, Estimated life		5 years
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets		5 years
Minimum [Member] | Leasehold Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Property and equipment, Estimated life		3 years

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets
Total Assets	$ 30,573	$ 24,635
Money market accounts
Assets
Total Assets	30,573	24,635
Level 1 [Member]
Assets
Total Assets	30,573	24,635
Level 1 [Member] | Money market accounts
Assets
Total Assets	$ 30,573	$ 24,635

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Reconciliation of Changes In Fair Value of Convertible Debentures (Detail) - Convertible Debentures [Member] - Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 13,642
Issuances	0
Fair value adjustments	7,522
Conversion	(21,164)
Ending balance	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Level 3 [Member]
Fair Value Disclosures [Line Items]
Assets Fair Value Disclosure Nonrecurring Loss	$ 0	$ 0

Revenue - Revenues Disaggregate

Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 33,638	$ 29,698	$ 31,340
Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	23,585	20,826	21,745
Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	7,875	6,994	7,184
Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,089	1,804	2,036
Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	89	29	153
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		45	222
Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	23,596	20,956	22,340
Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	10,042	8,742	9,000
Direct Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	19,134	17,582	17,772
OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	7,306	8,188	10,351
Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	7,198	3,928	3,217
Detection [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	22,019	21,997	22,319
Detection [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	15,661	16,291	16,788
Detection [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	6,358	5,661	5,370
Detection [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		45	161
Detection [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	15,584	16,332	16,949
Detection [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	6,435	5,665	5,370
Detection [Member] | Direct Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	14,713	13,809	11,968
Detection [Member] | OEM Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	7,306	8,188	10,351
Therapy [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	11,619	7,701	9,021
Therapy [Member] | Products [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	7,924	4,535	4,957
Therapy [Member] | Service Contracts [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	1,517	1,333	1,814
Therapy [Member] | Supply and Source Usage Agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	2,089	1,804	2,036
Therapy [Member] | Professional Services [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	89	29	153
Therapy [Member] | Other [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers		0	61
Therapy [Member] | Goods Transferred at a Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	8,012	4,624	5,391
Therapy [Member] | Services Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	3,607	3,077	3,630
Therapy [Member] | Direct Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	4,421	3,773	5,804
Therapy [Member] | Channel Partners [Member]
Disaggregation of Revenue [Line Items]
Revenue from contracts with customers	$ 7,198	$ 3,928	$ 3,217

Revenue - Summary of Receivable

Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Contract with Customer, Asset and Liability [Abstract]
Receivables, which are included in ‘Trade accounts receivable'	$ 8,891	$ 10,027
Current contract assets, which are included in "Prepaid and other assets"	1,895	481
Non-current contract assets, which are included in "other assets"	844	1,434
Contract liabilities, which are included in "Deferred revenue"	$ 6,093	$ 6,384	$ 5,604

Revenue - Summary of Changes in

Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Revenue Disclosure [Abstract]
Balance at beginning of period	$ 6,384	$ 5,604
Deferral of revenue	12,315	11,212
Recognition of deferred revenue	(12,606)	(10,432)
Balance at end of period	$ 6,093	$ 6,384

Revenue - Schedule of Changes o

Revenue - Schedule of Changes of Capitalized Costs to Obtain Contract (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Capitalized Contract Cost, Net [Abstract]
Balance at beginning of period	$ 406	$ 379
Deferral of costs to obtain a contract	249	157
Recognition of costs to obtain a contract	(353)	(130)
Balance at end of period	$ 302	$ 406

Revenue - Additional Informatio

Revenue - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Revenue From Contract With Customer [Line Items]
Unearned amount to recognize in 2022	$ 7.1
Unearned amount to recognize in 2023	1.2
Unearned amount to recognize in 2024	1
Unearned amount to recognize in 2025	$ 1

Net Loss per Common Share (1o_2

Net Loss per Common Share (1o) - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss available to common shareholders	$ (11,245)	$ (17,610)	$ (13,551)
Basic shares used in the calculation of earnings per share	24,778	22,140	18,378
Effect of dilutive securities:
Diluted shares used in the calculation of earnings per share	24,778	22,140	18,378
Net loss per share :
Basic	$ (0.45)	$ (0.80)	$ (0.74)
Diluted	$ (0.45)	$ (0.80)	$ (0.74)

Net Loss per Common Share (1o_3

Net Loss per Common Share (1o) - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,487,386	1,898,673	3,444,071
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	2,486,511	1,869,507	1,550,662
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	875	29,166	150,909
Convertible Debentures [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock			1,742,500

Inventories - Schedule of Curre

Inventories - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 2,962	$ 1,538
Work in process	173	76
Finished Goods	1,279	1,774
Inventory Gross	4,414	3,388
Inventory Reserve	(243)	(244)
Inventory Net	$ 4,171	$ 3,144

Goodwill and Intangible asset_2

Goodwill and Intangible assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Gross Carrying Amount
Gross Carrying Amount	$ 9,407	$ 9,383	$ 9,369
Accumulated Amortization
Accumulated Amortization	8,724	8,494	8,186
Total amortizable intangible assets, net	683	889	1,183
Patent and Licenses [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 619	595	581
Weighted average useful life	5 years
Accumulated Amortization
Accumulated Amortization	$ 534	529	520
Technology [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 8,257	8,257	8,257
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 7,769	7,571	7,299
Customer Relationships [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 272	272	272
Weighted average useful life	7 years
Accumulated Amortization
Accumulated Amortization	$ 162	135	108
Tradename [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 259	259	259
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 259	$ 259	$ 259

Goodwill and Intangible asset_3

Goodwill and Intangible assets - Schedule of Expected Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
2022	$ 217
2023	186
2024	103
2025	103
2026	74
Total amortizable intangible assets, net	$ 683	$ 889	$ 1,183

Goodwill and Intangible asset_4

Goodwill and Intangible assets - Additional Information (Detail) - USD ($)	Oct. 01, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Good will And Intangible Assets Disclosure [Line Items]
Goodwill		$ 8,362,000	$ 8,362,000
Additions to goodwill		0	0
Goodwill impairment	$ 0	0	0
Other changes to goodwill		0	0
Amortization		230,000	309,000	$ 377,000
ICAD Detection [Member]
Good will And Intangible Assets Disclosure [Line Items]
Goodwill		$ 8,362,000,000	$ 8,362,000,000

Accrued and Other Expenses - Ac

Accrued and Other Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued salary and related expenses	$ 2,016	$ 3,654
Accrued accounts payable	2,838	2,405
Accrued professional fees	497	598
Other accrued expenses	291	382
Accrued Expenses Total	$ 5,642	$ 7,039

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 31, 2021	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Lease incentives amount		$ 110,160
Increase in lease liability		79,000
Increase in right of use asset		$ 79,000
Nashua [Member]
Lessee, Lease, Description [Line Items]
Extended lease term of warehouse	2024

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating lease cost - Right of Use	$ 862	$ 884
Operating lease cost - Variable Costs	186	165
Finance lease costs
Total	1,048	1,049
Cash paid for operating cash flows from operating leases	$ 919	$ 909
Weighted-average remaining lease term of operating leases (in years)	1 year 3 months 29 days	2 years 2 months 15 days
Weighted-average discount rate for operating leases	5.50%	5.60%

Leases - Summary of Detained In

Leases - Summary of Detained Information of Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 931
2023	253
2024	16
Total	1,200
Less: imputed interest	(45)
Total lease liabilities	1,155
Less: current portion of lease liabilities	(889)
Total lease liabilities	$ 266	$ 1,075
Operating Lease, Liability, Statement of Financial Position [Extensible List]	Total lease liabilities

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Dec. 31, 2021	Mar. 02, 2021	Dec. 17, 2020	Apr. 27, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs	$ 4,300,000				$ 4,300,000
Period of expected recognized over a weighted average					1 year 8 months 12 days
ESPP offerings outstanding	2,486,511				2,486,511	1,869,507	1,550,662
Common stock, shares issued			470,704	1,562,500	168,450	155,149
Price per share, shares issued				$ 8
Gross proceeds from issuance of common stock			$ 6,600,000	$ 12,500,000
Net proceeds from issuance of common stock			$ 6,100,000	12,300,000	$ 23,229,000	$ 18,285,000	$ 9,353,000
Common stock, value of shares				$ 25,000,000	$ 23,229,000	$ 18,284,000	$ 9,353,000
Partners' Capital Account, Units, Sale of Units		1,393,738
Sale of Stock, Price Per Share		$ 18
Partners' Capital Account, Public Sale of Units Net of Offering Costs		$ 23,200
Underwriting Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of Stock, Price Per Share		$ 16.92
Reimbursement of expenses in connection with the offering		$ 125,000,000
2012 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	37,871				37,871
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	37,871				37,871
2016 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	1,718,200				1,718,200
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,718,200				1,718,200
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	950,000				950,000
Percentage of voting right not eligible for ESPP	5.00%				5.00%
Share-based payment award, maximum employee subscription rate	15.00%				15.00%
Share-based payment award, discount from market price, offering date					85.00%
Maximum amout of purchase allowed	$ 25,000,000
ESPP offerings outstanding	24,786				24,786	42,606
Common Stock, Capital Shares Reserved for Future Issuance	882,608				882,608
Amended Two Thousnad And Sixteen Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	4,700,000				4,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	4,700,000				4,700,000
Amended Two Thousnad And Sixteen Stock Option Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	2,600,000				2,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,600,000				2,600,000
Stock Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted					100.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity for all Stock Option plan (Detail) - $ / shares	Dec. 17, 2020	Apr. 27, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Beginning balance			1,869,507	1,550,662
Granted			865,938	563,502
Exercised	(470,704)	(1,562,500)	(168,450)	(155,149)
Forfeited			(80,484)	(89,508)
Ending Balance			2,486,511	1,869,507	1,550,662
weighted Average, Beginning Balance			$ 5.91	$ 4.33
Granted			16.33	10.09
Exercised			6.10	4.70
Forfeited			13.74	2.51
Weighted Average, Ending Balance			$ 9.27	$ 5.91	$ 4.33
Weighted Average Remaining Contractual Term, Outstanding			5 years 5 months 1 day	6 years
Exercisable, Number of Shares			1,619,855	1,540,287	881,461
Exerciable, Weighted Average Exercise Price			$ 6.47	$ 5.55	$ 4.43

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 2,783	$ 2,844	$ 1,168
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	15	30	3
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	356	376	226
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	785	657	226
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 1,627	$ 1,781	$ 713

Stockholders' Equity - Options

Stockholders' Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average rish-free interest rate	0.42%	0.65%	1.88%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average fair value	$ 7.22	$ 4.37	$ 2.34
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	67.40%	66.04%	54.23%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	65.57%	50.17%	50.01%

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Intrinsic Values of Options (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Outstanding	$ 3,820	$ 13,626	$ 5,465
Exercisable	3,730	11,786	3,067
Exercised	$ 1,453	$ 1,037	$ 509
Company's stock price at December 31	$ 7.20	$ 13.20	$ 7.77

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Restricted Stock Activity for All Equity Incentive Plans (Detail) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning outstanding balance	29,166	150,909	423,202
Granted	22,488	0	15,990
Vested	(50,779)	(118,077)	(197,730)
Forfeited	0	(3,666)	(90,553)
Ending outstanding balance	875	29,166	150,909

Allowance for Doubtful Accoun_3

Allowance for Doubtful Accounts - Schedule of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Receivables [Abstract]
Balance at beginning of period	$ 111	$ 136	$ 177
Additions charged to costs and expenses	167	94	62
Reductions	(10)	(119)	(103)
Balance at end of period	$ 268	$ 111	$ 136

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current provision:
Federal
State	0	$ 37	$ 42
Foreign	0
Current provision (benefit), Total	0	37	42
Deferred provision:
Federal	1	1	1
State			0
Foreign	0
Deferred provision, Total	1	1	1
Total	$ 1	$ 38	$ 43

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective and the Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Income Tax Expense [Line Items]
Federal statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	5.20%	2.40%	1.70%
Net state impact of deferred rate change	0.80%	(0.70%)	(0.20%)
Stock compensation expense	1.30%	0.90%	(10.70%)
Other permanent differences	(0.10%)	(0.10%)	0.00%
Change in valuation allowance	(24.40%)	(13.40%)	(6.00%)
Tax credits	3.10%	1.40%	2.80%
Accrual to tax return	(1.40%)	0.00%	1.30%
FV Mark to market on convertible notes	0.00%	(9.00%)	(10.40%)
Foreign Rate Differential	0.00%	0.00%	0.20%
True Ups—NOL Expiration/162(m) limits	(5.40%)	(2.80%)	0.00%
Effective income tax	0.10%	(0.30%)	(0.30%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Inventory (Section 263A)	$ 276	$ 248
Inventory reserves	61	60
Receivable reserves	67	28
Other accruals	854	1,081
Deferred revenue	107	75
Accumulated depreciation/amortization	8	37
Stock options	795	459
Developed technology	1,242	1,449
Tax credits	4,176	3,859
NOL carryforward	38,383	36,078
Lease liability	290	415
Deferred tax assets	46,259	43,789
Valuation allowance	(45,994)	(43,356)
Right of Use Asset	(265)	(433)
Goodwill tax amortization	(5)	(4)
Deferred tax liability	$ (5)	$ (4)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Income Tax Expense [Line Items]
Federal net operating loss carryforwards	$ 159,000,000
Net operating losses utilized	0	$ 0	$ 0
Unrecognized tax benefits	0	0
Interest or penalties related to uncertain tax positions	$ 0	0	$ 0
Company preceding tax years	3 years
Tax credits	$ 4,176,000	$ 3,859,000
Expire Between 2019 And 2037 [Member]
Schedule Of Income Tax Expense [Line Items]
Federal net operating loss carryforwards	120,100,000
Indefinite Period [Member]
Schedule Of Income Tax Expense [Line Items]
Federal net operating loss carryforwards	$ 39,000,000
Minimum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2022
Maximum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2037
Xoft Inc [Member]
Schedule Of Income Tax Expense [Line Items]
Net operating losses that are subject to limitations	$ 5,200,000
Net operating losses that are subject to limitations that can be used through 2029	656,000
Future Income tax liabilities offset With operation loss carryforward	$ 4,200,000
Tax credit carryforward expiration year	2041
Tax credits	$ 1,800,000

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)customer	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Schedule Of Geographical Information [Line Items]
Number of reporting segments | customer	2
Percentage of export sales to any single country	10.00%
Outstanding receivables	$ 8,891	$ 10,027
Total Revenue	$ 33,638	$ 29,698	$ 31,340
Percentage of receivables	100.00%	100.00%	100.00%
GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 7,000
Percentage of receivables	2.00%
OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 5,500
Three Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	2,800
Detection OEM [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 3,000
Percentage of receivables	3.00%
Sales [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales	$ 8,000
Total Revenue	4,800	$ 5,000	$ 7,600
Revenues	$ 8,000
Sales [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	14.00%	17.00%	24.00%
Sales [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables		28.00%	33.00%
Sales [Member] | Customer Concentration Risk [Member] | OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	26.00%
Sales [Member] | Customer Concentration Risk [Member] | Four OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	19.00%
Sales [Member] | Detection [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables		37.00%	46.00%
Sales [Member] | Detection [Member] | Customer Concentration Risk [Member] | OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	40.00%
Sales [Member] | Detection [Member] | Customer Concentration Risk [Member] | Four OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	29.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	8.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | OEM Partners [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	60.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables	31.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Detection OEM [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	$ 8,600
Percentage of receivables	94.00%
Non-US [Member]
Schedule Of Geographical Information [Line Items]
Percentage of export sales of total sale	22.00%	20.00%	12.00%
Total Export Sales	$ 7,500	$ 6,100	$ 3,800
Outstanding receivables	3,300	3,400
Revenues	$ 7,500	$ 6,100	$ 3,800

Segment Reporting - Summary of

Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment revenues:
Total Revenue	$ 33,638	$ 29,698	$ 31,340
Segment gross profit:
Total gross profit	24,243	21,354	24,227
Segment operating income (loss):
Segment operating income (loss)	(272)	(309)	1,088
General administrative	(10,460)	(9,079)	(7,486)
Interest expense	(141)	(476)	(784)
Loss on extinguishment of debt	(386)	(341)	0
Other income	15	97	345
Fair value of convertible debentures	0	(7,464)	(6,671)
Loss before income tax expense	(11,244)	(17,572)	(13,508)
Product [Member]
Segment revenues:
Total Revenue	21,191	18,903	19,767
Service [Member]
Segment revenues:
Total Revenue	12,447	10,795	11,573
Detection [Member]
Segment gross profit:
Total gross profit	18,510	17,856	18,627
Segment operating income (loss):
Segment operating income (loss)	1,563	2,719	2,564
Detection [Member] | Product [Member]
Segment revenues:
Total Revenue	22,019	21,997	22,319
Therapy [Member]
Segment gross profit:
Total gross profit	5,733	3,498	5,600
Segment operating income (loss):
Segment operating income (loss)	(1,835)	(3,028)	(1,476)
Therapy [Member] | Service [Member]
Segment revenues:
Total Revenue	$ 11,619	$ 7,701	$ 9,021

Segment Reporting - Summary o_2

Segment Reporting - Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss) (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	$ 327,000	$ 268,000	$ 297,000
Amortization	230,000	309,000	377,000
Detection [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	123,000	115,000	103,000
Amortization	158,000	164,000	240,000
Therapy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	129,000	124,000	166,000
Amortization	$ 73,000	$ 128,000	$ 128,000

Segment Reporting - Summary o_3

Segment Reporting - Summary of Concentration of Revenue by Geographic Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	100.00%	100.00%	100.00%
Total Export sales	$ 7,527	$ 6,081	$ 3,788
Europe
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	39.00%	45.00%	57.00%
Taiwan
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	12.00%	13.00%	15.00%
Canada
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	3.00%	5.00%	7.00%
China
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	35.00%	22.00%	8.00%
Other
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	11.00%	15.00%	13.00%
France
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	47.00%	41.00%	34.00%
Spain
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	17.00%	17.00%	12.00%
Germany
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	4.00%	12.00%	4.00%
Italy
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	5.00%	8.00%	2.00%
United Kingdon
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	4.00%	6.00%	2.00%
Russia
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	8.00%	0.00%	0.00%
Switzerland
Schedule Of Concentration Of Revenue By Geographic Area [Line Items]
Percent of Export sales	8.00%	0.00%	0.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Apr. 13, 2021	Jun. 30, 2021	Dec. 31, 2021	Jan. 30, 2017	Dec. 31, 2016
Schedule Of Leases [Line Items]
Purchase obligations to suppliers for future product deliverables			$ 7,200,000
Minimum annual royalty payment			250,000
Fair value of patent license			$ 100,000
Patent license, Estimated Amortizable Life			4 years
Minimum royalty obligations			$ 200,000
Cash paid on litigation	$ 85,000
Escrowed amount payable by other party		$ 50,000
Litigation Settlement, Expense		$ 93,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Schedule Of Leases [Line Items]
Sale and transfer of intangible assets					$ 3,200,000
Holdback reserve related to sale and transfer of intangible assets				$ 350,000
Proceeds from sale and transfer of intangible assets				$ 2,900,000

Notes Payable - Schedule of Key

Notes Payable - Schedule of Key Inputs to Simulation Model Utilized to Estimate Fair Value of Convertible Debentures (Detail) - Convertible Debt [Member]		Feb. 21, 2020yr	Dec. 31, 2019yr
Company's Stock Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		11.64	7.77
Conversion Price [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		4	4
Remaining Term (Years) [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input		0	1.97
Equity Volatility [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			49
Risk Free Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input			1.57
Probability of Default Event [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		0.45
Utilization of Forced Conversion [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]	100	100
Exercise of Default Redemption [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		100
Effective Discount Rate [Member]
Debt Instrument [Line Items]
Debt Instrument Measurement Input	[1]		18.52
[1]	Represents a Level 3 unobservable input, as defined in Note 8 – Fair Value Measurements, below.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail)	Apr. 27, 2021USD ($)	Mar. 30, 2020USD ($)	Dec. 31, 2021USD ($)customer$ / shares	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)	Feb. 21, 2020USD ($)	Feb. 21, 2019USD ($)	Aug. 07, 2017USD ($)
Debt Instrument [Line Items]
Loss from fair value of the convertible debentures				$ 7,500,000
Final payment of loan			$ 510,000
Gain (Loss) on Extinguishment of Debt			(386,000)	(341,000)	$ 0
Reclassified the fair value of convertible debentures					13,642,000	$ 21,164,000	$ 21,200,000
Repayments of Lines of Credit	$ 7,354,283,000			$ 2,775,000	$ 1,000,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Termination Loans			114,000
Gain (Loss) on Extinguishment of Debt		$ 341,000,000
Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Final payment of loan		185,000
Termination Loans		114,000
Other Costs		10,000
Unamortized closing costs		42,000
Western Alliance Bank [Member]
Debt Instrument [Line Items]
Gain (Loss) on Extinguishment of Debt			386,000
Western Alliance Bank [Member] | Debt Prepayment Cost [Member]
Debt Instrument [Line Items]
Debt prepayment cost			140,000
Western Alliance Bank [Member] | Final Payment Of Loan [Member]
Debt Instrument [Line Items]
Final payment of loan			122,000
Western Alliance Bank [Member] | Termination Loans [Member]
Debt Instrument [Line Items]
Termination Loans			65,000
Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member]
Debt Instrument [Line Items]
Unamortized closing costs			58,000
Convertible Debt [Member]
Debt Instrument [Line Items]
Aggregate principal amount			$ 7,000,000
Debt conversion, conversion price per share | $ / shares			$ 4
Convertible debenture Number of instrumnts converted | customer			1,742,500
Shares issued up on conversion | shares				1,816,466
Convertible Debt [Member] | Make Whole Provision [Member]
Debt Instrument [Line Items]
Aggregate principal amount			$ 697,000
Convertible debenture Number of instrumnts converted | customer			76,966
Term Loan A [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		7,000,000						$ 6,000,000
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Credit facility		$ 5,000,000						$ 4,000,000

Notes Payable - Schedule of Fai

Notes Payable - Schedule of Fair Value and Principal Value of Convertible Debentures (Detail) - USD ($) $ in Thousands	Feb. 21, 2020	Dec. 31, 2019	Feb. 21, 2019
Debt Disclosure [Abstract]
Fair value, in accordance with fair value option	$ 21,164	$ 13,642	$ 21,200
Principal value outstanding	$ 6,970	$ 6,970

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - 401 k Plan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan,Percentage of Compensation elect to contribute by participant	90.00%
Defined benefit plan,Employer matching contribution percent of every dollar contributed	100.00%
Defined benefit plan,Employer matching contributions not exceed the percent of participant's eligible wages	3.00%
Defined benefit plan,Employer contributed amount	$ 5	$ 5